Standard BioTools Inc. Other Nonoperating Expense
Standard BioTools Inc. (LAB) reported Other Nonoperating Expense of $2.23 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-09.
Discontinued › Income Statement › Other Income
us-gaap:OtherNonoperatingExpense · last filed 2024-05-09
- Standard BioTools Inc. other nonoperating expense for the quarter ending 2024-03-31 was $2.23M, a 3686.44% increase year-over-year.
- Standard BioTools Inc. other nonoperating expense for the quarter ending 2023-03-31 was $59.00K.
| Period end | Other Nonoperating Expense 3 month |
|---|---|
| 2024-03-31 | $2.23M 10-Q · filed 2024-05-09 |
| 2023-03-31 | $59.00K 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |